Skip to main content
Посетете глобалния сайт на Janssen
 
 
 

Bulgaria
Изберете държава▼

Търсене
Търсене
COVID-19 новини >

Добре дошли в Janssen България

VISIT JANSSEN GLOBAL

Janssen България › медиен център

Media Center

The Media Center is intented to provide resources for media professionals only. It is not inteded for use by healthcare professionals, patients or the general public. To access, please confirm that you are an accredited member of the press. I hereby confirm that I am an accredited member of the press
I Agree
Cancel

Press Releases

Jan 21, 2019

JANSSEN SUBMITS APPLICATION TO EUROPEAN MEDICINES AGENCY SEEKING APPROVAL OF STELARA® (USTEKINUMAB) FOR TREATMENT OF ADULT PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS 

Jan 21, 2019

New Phase 3 data demonstrate superiority of TREMFYA®▼ (guselkumab) vs Cosentyx® (secukinumab) in delivering PASI 90 responses in the treatment of moderate to severe plaque psoriasis at week 48 

Jan 17, 2019

Janssen announces European Commission approval of ERLEADA® (apalutamide) for non-metastatic castration-resistant prostate cancer patients who are at high risk of developing metastatic disease

Dec 23, 2018

Janssen Announces European Commission Approval of Darzalex®▼ (daratumumab) Split Dosing Regimen 

Dec 06, 2018

Data Presented at ASH 2018 Provide Evidence of First-line Treatment Benefits with IMBRUVICA®▼ (ibrutinib)-Based Therapy Across All Patient Populations in CLL

Dec 06, 2018

Updated Data from Phase 1/2 Open-Label Study of BCMA-Directed CAR-T Cell Therapy LCAR-B38M Show Tolerable Safety Profile, High Overall Response and MRD Negative Rate in Treatment of Patients with Advanced R/R Multiple Myeloma1

View more Press Releases

Media Backgrounders

Janssen Research Global Collaboration

Investing in European Health R&D

Janssen Health Policy Centre

Investing in European Health R&D - Executive Summary

About Xeplion

About Schizophrenia

VIEW MORE MEDIA BACKGROUNDERS

VIRTUAL ONCOLOGY PRESSROOM

Quick Links

 

Tweets

 
Follow us on Twitter
SUBSCRIBE TO OUR YOUTUBE CHANNEL
Вие напускате страницата поддържана от Janssen България. Ако натиснете бутона „Продължи" ще бъдете пренасочени към интернет страница, която не се регулира от законите на Република България. Janssen България не носи отговорност за съдържанието на тази интернет страница.
Продължи
Обратно